Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06857942 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

StatusRecruiting
PhasePhase 4
Started2025-03-19
View on ClinicalTrials.gov ↗
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.

Amendment record

Amended 18 times since 2025-03-03; most recent filed 2026-06-02. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-30.

2026-06-02
Amendment Study Status, Contacts/Locations v18
2026-05-13
Amendment Study Status, Contacts/Locations v17
2026-04-16
Amendment Study Status, Contacts/Locations v16
2026-03-18
Amendment Study Status, Contacts/Locations v15
2026-01-12
Amendment Study Status, Contacts/Locations v14
2025-11-21
Amendment Study Status, Contacts/Locations v13
2025-11-05
Amendment Study Status, Contacts/Locations v12
2025-10-15
Amendment Study Status, Contacts/Locations v11
2025-10-08
Amendment Study Status, Contacts/Locations v10
2025-09-25
Amendment Study Status, Contacts/Locations v9
2025-09-08
Amendment Study Status, Contacts/Locations v8
2025-08-25
Amendment Study Status, Contacts/Locations v7
2025-07-17
Amendment Study Status, Contacts/Locations v6
2025-06-24
Amendment Study Status, Contacts/Locations v5
2025-05-23
Amendment Study Status, Contacts/Locations v4
2025-04-17
Amendment Study Status, Contacts/Locations v3
2025-03-27
Amendment Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
2025-03-10
Amendment Study Identification, Study Status, Outcome Measures, References v1
2025-03-03
Original filing
Trial Details
NCT Number NCT06857942
Lead Sponsor Eli Lilly and Company
Conditions Psoriasis, Overweight or Obesity
Enrollment 200 participants
Start Date 2025-03-19
Primary Completion 2028-05 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-09-04